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Chemotherapy is one of the standard methods of treatment in many cancers. While chemotherapy is often capable
of inducing cell death in tumors and reducing the tumor bulk, many cancer patients experience recurrence and
ultimately death because of treatment failure. In recent years, cancer stem cells (CSCs) have gained intense interest
as key tumor-initiating cells that may also play an integral role in recurrence following chemotherapy. As such, a
number of mechanisms of chemoresistance have been identified in CSCs. In this review, we describe a number of
these mechanisms of chemoresistance including ABC transporter expression, aldehyde dehydrogenase (ALDH)
activity, B-cell lymphoma-2 (BCL2) related chemoresistance, enhanced DNA damage response and activation of key
signaling pathways. Furthermore, we evaluate studies that demonstrate potential methods for overcoming
chemoresistance and treating chemoresistant cancers that are driven by CSCs. By understanding how
tumor-initiating cells such as CSCs escape chemotherapy, more informed approaches to treating cancer will
develop and may improve clinical outcomes for cancer patients.
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Our understanding of cancer has changed over the years,
owing to rapid advances in oncology research. The disease
itself is not only characterized as a mass of excessive, un-
controlled growth of abnormal cells but is also defined by
the dynamic alterations in the genome that cause cancer
[1]. Left unchecked, cancer progression leads to disruption
of normal biological processes via cellular invasion into
local adjacent tissues and distal organs through metastasis.
In addition to conventional cancer treatments such as sur-
gery, radiation and cytotoxic chemotherapy, more selective
treatments based on increased understanding of tumor
biology and specific tumor subtypes have also become
available [2]. Even with these advances in cancer therapy,
chemotherapy remains an important component of cancer
treatment. Currently, the complete elimination of cancer
continues to elude oncologists as 90% of drug failures in
metastatic cancers are attributed to chemoresistance [3].
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approaches to treating cancer.
In some cases, intrinsic chemoresistance may result in
the survival of a population of tumor cells that subse-
quently leads to recurrence following treatment. This may
be particularly true for tumors that are composed of a he-
terogeneous population of cells. For heterogenous tumors,
the tumor initiating potential and drug sensitivity of differ-
ent tumor cells within the same tumor bulk has yielded
two models of cancer initiation: the stochastic model and
the hierarchical model [4]. The stochastic model proposes
that there is no variation in tumor initiating potential
among different tumor subpopulations and that tumor cell
growth is dependent on immune response, microenviron-
ment and intrinsic gene regulatory signals. In contrast, the
hierarchical concept suggests that different subpopulations
of cells within a tumor have varying levels or absence of
tumor initiating potential. Those fractions of cells that
have enhanced tumor initiating potential are referred to as
cancer stem cells (CSC). While CSC are not necessarily
derived from normal stem cells, defining characteristics of
CSCs include the ability to self-renew as well as differen-
tiate into other tumor cell subtypes.This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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many decades and suggested as a mechanism for tumor
initiation in both hematological malignancies as well as
solid tumors such as breast cancer [5]. While it is now
clear that not all heterogenous cancers follow the hierarch-
ical model [6], there is growing evidence for a role of CSCs
in a number of cancers. Early evidence for CSCs was first
seen in hematological malignancies. In 1994, Lapidot et al.
identified a subpopulation of tumor-initiating cells in acute
myelogenous leukemia (AML) [7]. The identification of
these leukemic initiating cells was based on differential ex-
pression of cell surface markers CD34 and CD38 where
only CD34+/CD38- AML cells could give rise to leukemic
growth in severe combined immodeficiency (SCID) mice
even though they represented a small fraction in the total
leukemic population. Additionally, these cells demon-
strated self-renewal and differentiation through recapitula-
ting the entire hierarchy of human leukemia in a mouse.
Thus, this work described important properties that are
utilized now to identify CSCs, namely tumor-initiation,
self-renewal and differentiation. This work led to one of
the earliest descriptions of leukemic stem cells (LSCs)
based on specific surface marker expressions and provided
strong evidence for the existence of CSCs in cancer. While
hematological malignancies provide the greatest evidence
for the existence of CSCs, a number of studies have identi-
fied tumor-initiating CSCs in solid tumors as well. These
CSCs were also identified based on phenotypic markers in-
cluding surface protein expression and biological properties
similar to those seen in normal stem and progenitor cells.
This was demonstrated by Al-Hajj et al. when describing
tumor-initiating breast CSCs [8]. In this study, primary
human breast tumor cells were evaluated for tumor-
initiating properties through orthotopic injection of these
cells into mammary fat pads of NOD/SCID mice. This
work identified ESA+CD44+CD24-/low breast tumor cells as
having greater tumorigenicity than cells lacking these mar-
kers. Furthermore, similar to studies with AML, secondary
tumors from CSC xenografts contained heterogenous
populations of tumor-initiating CSCs and non-tumorigenic
daughter cells that lack these markers. Thus, these breast
CSCs were capable of self-renewal and differentiation, hall-
marks of both normal and cancer stem cells. Following this
study, a number of reports have identified CSCs in solid
tumors based on other surface markers such as CD133,
EpCAM and CD90 as well as phenotypic markers such as
side population (SP) or aldehyde dehydrogenase (ALDH)
activity [9-13]. This includes the identification of solid
tumor CSCs in a variety of organs including liver, brain,
colon, pancreas, lung, ovaries and prostate [9-11,14-17].
The ability to identify and isolate CSCs in various
tumor models has now led to the emergence of studies
that are beginning to understand the mechanisms by
which CSCs can contribute to tumor initiation as well ascontinued tumor progression. In some cases, CSCs ap-
pear capable of driving tumor population expansion and
relapse following treatment through chemoresistance.
While the mechanisms by which CSCs can escape
chemotherapy treatment appear to be diverse, our stu-
dies suggest that these mechanisms may be influenced
by specific oncogenes that are integral to a tumor’s ini-
tiation and subsequent growth [18]. In this review, we will
discuss some of the mechanisms by which CSCs can es-
cape chemotherapy as well as the clinical implications of
these studies. Understanding the mechanisms by which
CSCs can contribute to chemotherapy and tumor relapse
is important as it provides important clues to better
addressing cancer therapy and more specifically, cancer
therapy that accounts for the unique biology of CSCs.ABC transporters and CSCs
Following chemotherapy, primary and metastatic sites of
recurrence are often attributed to cells that have escaped
chemotherapy. Because CSCs have been proposed to be
the key tumor-initiating cell during recurrence, research-
ers have looked at chemoresistance as a functional me-
chanism by which one can identify and isolate CSCs. One
such method that has proven useful in many different
models of cancer is the identification of CSCs by enhanced
efflux of Hoechst 33342 dye through ATP-binding cassette
(ABC) transporters. Defined as side population (SP) cells
during flow cytometry analysis, they were initially demon-
strated to be useful in isolating hematopoetic stem cells
[19]. One of the earliest studies demonstrating SP analysis
as a method for enriching for CSCs occurred utilizing the
C6 rat glioma cell line [12]. In this study, SP cells were
demonstrated to be the key tumor-initiating CSCs for the
C6 cell line. Additionally, SP cells could repopulate both
SP and non-SP cells suggesting that these cells possess the
hallmark properties of CSCs, namely self-renewal and dif-
ferentiation. Following this study, SP analysis has been
used to identify CSCs in a wide variety of solid tumors, in-
cluding breast, colon, ovarian and hepatic cancers [20-23].
Recently, we identified that while SP is a useful method
for enriching for CSCs in hepatic cancer, this mechanism
of chemoresistance is not a universal feature of hepatic
CSCs [18]. In fact, the presence of SP cells in tumors was
found to be highly dependent on the driving genetic
alterations of the tumor. In the case of our study, hepatic
tumors driven by MYC, but not AKT and RAS, had a sig-
nificant number of SP cells that appeared to enrich for
chemoresistant tumor-initiating CSCs. This study pro-
vided evidence that while these mechanisms of chemore-
sistance appear common, they may differ depending on
the driving genomic alterations of cancer. Understanding
how such genomic alterations result in different cancer
phenotypes amongst patients will allow clinicians to make
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cancers unique to specific patients.
CSCs identified as SP cells exhibit chemoresistance
related to the ABC transporter expressed in these cells.
Two ABC transporters have been identified as capable of
effluxing Hoechst 33342 dye and mediating the SP pheno-
type in CSCs as well as normal cells; P-glycoprotein
(MDR1) and breast cancer resistance protein (ABCG2)
[18,24,25]. ABC transporters are generally located in the
cellular plasma membrane and function in normal biology
to protect cells from harmful toxins and xenobiotics.
MDR1 is primarily found in the kidney, adrenal glands, ca-
pillary blood vessels of the brain and also in the placenta
[26]. In normal cells, MDR1 is usually present at low levels
and is responsible in preventing the entry of foreign toxins
into the growing fetus or sensitive organs such as the
brain. ABCG2 is found in milk ducts of the mammary
gland, hematopoietic stem cells and the blood brain bar-
rier [27-29]. Some drugs, such as doxorubicin (Dox), are
effluxed by both ABCG2 and ABCB1. SP cells exhibit che-
moresistance to Dox regardless of which ABC transporter
is expressed [30]. Other drugs, such as paclitaxel, can only
be effluxed by MDR1 and not ABCG2 [18,30]. Thus, we
have demonstrated that SP cells that express primarily
MDR1 are more resistant to paclitaxel but not ABCG2-
specific drugs such as SN-38 [18,31].
Depending on the ABC transporter that mediates the SP
phenotype, one method of overcoming this mechanism of
chemoresistance involves the use of specific inhibitors of
ABC transporters. While clinical trials for general ABC
transporters such as verapamil have been performed, these
studies were ended due to the dose-limiting toxic side
effects of these molecules [32]. More specific molecules
related to individual ABC transporter pumps are currently
being tested [33]. Another method for overcoming this
chemoresistance that has also shown promise is the use of
nanoparticle drug-delivery of chemotherapeutics. We pre-
viously demonstrated that conjugation of Dox to nanodia-
monds impaired efflux of Dox in MDR1 overexpressing
cells and can improve the efficacy of Dox therapy in Dox-
resistant tumor models [34]. As such, while ABC transpor-
ters are a major mechanism of chemoresistance, there is
evidence that specific and non-specific methods of over-
coming ABC transporter pump activity may be useful for
improving chemotherapy against CSCs.
Aldehyde dehydrogenase related chemoresistance
In addition to the identification of CSCs by SP analysis,
another reported functional marker of CSCs is ALDH
activity. Enhanced ALDH activity also appears to confer
resistance to specific chemotherapeutics as well. ALDH1
is a cytosolic enzyme that oxidizes aldehydes and con-
verts them into carboxylic acids [35]. In addition to
ALDH1, there are 16 other isoforms of ALDH in thehuman body that also localize to the mitochondria in
addition to cytosol l [36]. While various isoforms are
expressed throughout the body, the kidney and liver have
been observed to express the highest levels of ALDH. In
normal liver function, ALDH1 functions as a cytosolic
retinal dehydrogenase that irreversibly converts retinol
(vitamin A) into retinoic acid [37]. The importance of re-
tinoic acids in embryonic development and stem/progenitor
cell differentiation has led to the identification of high
expression of ALDH in primitive hematopoietic pro-
genitors as well as in embryonic multipotent neuronal
stem cells [38-40].
Because ALDH activity has been linked to normal mul-
tipotent stem and progenitor cells, ALDH activity has
been extensively analyzed in candidate CSCs as a potential
marker for CSCs. Acute myeloid leukemic cells with ele-
vated ALDH activity appeared to have better engraftment
potential in NOD/SCID mice than their ALDH negative
counterparts [13]. In a study of normal and malignant
mammary cells, Ginestier et al. demonstrated that on
average 8% of normal mammary epithelial cells had
ALDH activity as measured by ALDEFLUOR-positive
staining [41]. Furthermore, ALDEFLUOR-positive breast
cancer cells that had ALDH activity were capable of
forming xenograft tumors with as little as 500 cells.
ALDEFLUOR-negative cells from the same tumor sam-
ples, however, were unable to form xenograft tumors with
as many as 50,000 cells. When ALDEFLUOR-positive
staining was combined with CD44+/CD24- markers, as
little as 20 breast cancer cells could form tumors. In
addition to breast cancer, a number of other solid tumors
such as lung, pancreas, prostate, liver and head and neck
squamous cancer have also demonstrated some evidence
of ALDH activity as a marker for CSCs [42-46].
Long before ALDH activity was used as a marker for
identifying CSCs, the potential role of ALDH in che-
moresistance had already been identified. In 1984, John
Hilton identified a chemoresistant role for ALDH in a
cyclophosphamide-resistant L1210 leukemic cell line
[47]. Studying the mechanisms of cyclophosphamide-
resistance, he identified that this cell line had unusually
high levels of ALDH activity and that cyclophosphamide
resistance could be reversed by inhibition of ALDH acti-
vity with disulfiram. Subsequent studies by Friedman et al.
confirmed the role of ALDH-mediated cyclophosphamide
resistance in medulloblastoma [48]. Since these initial stu-
dies, the ability of ALDH expression to confer resistance to
cyclophosphamide has been demonstrated in other cancer
systems and it is presumed that high ALDH activity is indi-
cative of cyclophosphamide resistance in cancer and CSCs
[49]. Thus, inhibition of ALDH activity can serve to
sensitize CSCs to chemotherapeutics such as cyclophos-
phamide. A study of early passage colon cancer xenograft
tumors revealed that treatment with cyclophosphamide
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the surviving tumor cells. Furthermore, these colon CSCs
exhibited high levels of ALDH activity. Treatment of
these ESA+CD44+ colon CSCs with ALDH inhibitors
or ALDH1A1-targeted siRNA resulted in increased sen-
sitivity to cyclophosphamide demonstrating that the
chemoresistance seen in their model was specifically
attributed to elevated ALDH activity [50]. In addition to
conferring resistance to cyclophosphamide, ALDH1A1
knockdown experiments in human pancreatic adenocarcin-
oma suggest that ALDH may also be capable of mediating
resistance to gemcitabine as well [51]. Continued studies
with direct ALDH inhibitors or inhibitors of pathways that
influence ALDH expression may provide useful tools in
overcoming chemoresistance in CSCs or directly impairing
CSC growth [44,52-54].
Pro-survival BCL-2 protein family members in CSCs
Another mechanism of chemoresistance that has been well
explored in CSCs is the role of B-cell lymphoma-2 (BCL-2)
protein and its family members. The BCL-2 protein family
has been identified as a group of proteins that play an inte-
gral role in maintaining the balance between cell survival
and apoptosis. BCL-2 primarily mediates its pro-survival
effects by binding to the pro-apoptotic proteins BCL2-
associated-X-protein (BAX) and BCL-2 homologous anta-
gonist killer (BAK) and impairing their ability to release
apoptogenic proteins such as cytochrome c from the mito-
chondria [55]. Originally identified as a putative oncogene
in acute B cell leukemia, BCL-2 is expressed in a number
of different neoplastic cells as well as a variety of he-
matopoietic lineage cells [56,57]. In addition to BCL-2,
there are four other pro-survival family members including
B-cell lymphoma extra large (BCL-XL), BCL-2-like-2
(BCL-W), BCL-2-related protein A1A (BCL-A1A) and
myeloid cell leukemia sequence-1 (MCL1) [58]. Knockout
studies have revealed key roles for these proteins in normal
biology that include the survival of a number of progenitor
cells including renal epithelial progenitors, melanocyte pro-
genitors, fetal erythroid progenitors, neuronal cells, sperm
cells and hematopoietic stem cells [59-63]. In addition to
their role in normal biology, pro-survival members of the
BCL-2 protein family have been identified as critical pri-
mary or secondary oncogenic events during tumorigenesis.
This was initially suggested during the identification of
BCL-2 by chromosomal translocation analysis that also
revealed the abnormal chromosomal translocation of the
MYC oncogene in an acute B-cell leukemia patient [56].
The role of BCL-2 in tumorigenesis was further confirmed
in Eμ-Myc/Eμ-Bcl-2 double transgenic mice where mice
that overexpressed both MYC and BCL-2 became termin-
ally ill from leukemia within 50 days while mice that solely
expressed MYC required up to 100 days to succumb to
malignancy [64].Considering the potent effect of BCL-2 family mem-
bers on tumorigenesis and cancer cell survival, their role
in CSC biology has been extensively studied. Konopleva
et al. demonstrated that quiescent leukemic CD34+ pro-
genitor cells highly expressed BCL-2 and BCL-XL [65].
Furthermore, differentiation of these cells with all-trans
retinoic acid resulted in lower expression of these pro-
survival proteins as well as increased sensitivity to cytosine
arabinoside [65]. Madjd et al. also showed that BCL-2 was
highly expressed in CD44+/CD24-/low breast CSCs [66].
While the mechanism of expression of these proteins is
unclear in all cancer models and may result from chromo-
somal translocation, work in CSCs also suggests that these
proteins can be expressed and affect chemoresistance
through induction by other signaling pathways required for
CSC survival. In CD133+ colon cancer stem cells, Todaro
et al. demonstrated that interleukin-4 (IL-4) was produced
and utilized in an autocrine manner. When CD133+ colon
CSCs were treated with IL-4 neutralizing antibodies a
decrease in BCL-XL as well as an increased sensitivity to
oxaliplatin and 5-fluorouracil (5-FU) was observed [67].
Ma et al. demonstrated that the AKT/PKB signaling path-
way regulated BCL-2 expression in CD133+ human HCC
cancer cells [68]. In the human HCC cancer cell line
Huh7, CD133+ CSCs appeared to express higher levels of
BCL-2 than their CD133- counterparts. Treatment of these
Huh7 and PLC8024 HCC cell lines with Dox or 5-FU
resulted in increased selection for chemoresistant CD133+
cells that expressed higher levels of both activated phos-
phorylated and BCL-2. Treatment with an AKT1 specific
inhibitor resulted in the potent loss of BCL-2 expression in
CD133+ cells as well as an increased sensitivity of these
cells to Dox or 5-FU that was equivalent to their CD133-
counterparts suggesting that BCL-2 induction by AKT1
may be a mechanism by which CSCs can mediate che-
moresistance. Another mechanism by which BCL-2 family
members may be induced in CSCs is through Aurora-A, an
oncogenic serine/threonine kinase that regulates cell cycle
[69,70]. Analysis of CD133+CD29+CD20- colorectal CSCs
revealed that these cells expressed high levels of Aurora-A
as well as BCL-2, MCL-1 and BCL-XL [69]. Knockdown of
Aurora-A by shRNA resulted in a strong reduction of
BCL-2 and MCL-1 expression and a moderate decrease in
BCL-XL expression. Similar to work by Todaro et al. the
decrease in pro-survival BCL-2 family member proteins
was associated with increased sensitivity to oxaliplatin and
5-FU. This work offers yet another pathway by which CSCs
may drive BCL-2-related chemoresistance and a potential
therapeutic target for overcoming this chemoresistance.
Role of CSC-related signaling pathways in
chemoresistance
In addition to the roles that MYC and AKT1 may play in
chemoresistance, there are a number of other signaling
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CSC biology, including chemoresistance. One such path-
way is the WNT/β-catenin signaling pathway, which is
required for normal stem and CSC self-renewal in a num-
ber of cell types [71-73]. In an early study of tumorigenic
OV6+ HCC progenitor cells, chemical activation of the
WNT pathway enhanced renewal of OV6+ hepatic CSCs
whereas lentiviral microRNA knockdown of β-catenin
impaired this self-renewal. These OV6+ hepatic CSCs also
exhibited enhanced chemoresistance to cisplatin that
could be reversed by lentiviral microRNA knockdown of
β-catenin [74]. Similar studies demonstrate that WNT/β-
catenin signaling pathway can also confer chemoresistance
to 5-FU and Dox [75,76]. While the mechanisms by which
the WNT pathway mediates chemoresistance in not com-
pletely clear in all these studies and likely varies amongst
cell lines and tumor types, one potential mechanism is
through the upregulation of ABC transporter pumps. In
chemoresistant neuroblastoma cells, activation of the
WNT pathway by FZD1 induced MDR1 and Dox resist-
ance [76]. In c-kit+ ovarian CSCs, chemoresistance to cis-
platin and paclitaxel was demonstrated to be mediated
ABCG2. ABCG2 expression and chemoresistance to both
cisplatin and paclitaxel could be reversed by β-catenin
siRNA knockdown [77].
Another signaling pathway that appears to play a role in
both CSC maintenance and chemoresistance is the Notch
signaling pathway. The Notch signaling pathway has been
identified to play an important role in a number of pro-
cesses during tumor progression and metastases including
tumor initiation, angiogenesis, epithelial-mesenchymal tra-
nsition (EMT)-driven metastatic growth as well as self-
renewal of cancer stem cells [78]. Recent evidence
suggests that Notch may also contribute to certain
mechanisms of chemoresistance in cancer stem cells. In
multiple colon cancer cell lines, treatment with oxaliplatin
induced Notch activation. Furthermore, siRNA knock-
down of Notch 1 or γ-secretase inhibitor (GIS) treatment
that prevents Notch pathway activation could sensitize
colon cancer cells to oxaliplatin and prevent chemoresis-
tance [79]. In addition to a potential role in colon cancer
cells, Notch proteins have been identified to be upregu-
lated in ovarian CSCs and GIS treatment appears to
sensitize ovarian CSCs to cisplatin through inhibition of
Notch maintenance of MDR1 expressing CSCs [80,81].
Notch also appears to contribute to chemoresistance in
CD133+ glioma CSCs in coordination with another signal-
ing pathway that has previously been identified to regulate
self-renewal in both normal and cancer stem cells, the
Sonic hedgehog (SHH) pathway [82,83]. Abnormal activa-
tion of the SHH pathway has been reported in a number
of CSC models [84]. While the specific mechanisms are
not clear, inhibition of the SHH pathway has been demon-
strated to sensitize CSCs in a variety of tumor typesincluding gastric cancer, pancreatic cancer, ovarian cancer
and prostate cancer [84-87].
Regulators of inflammation, such as the NF-κB pathway,
can also contribute to chemoresistance. A key mediator of
the inflammatory response, NF-κB has a diverse set of bio-
logical function that can contribute to both pro-tumorigenic
and anti-tumorigenic responses [88]. Constitutive acti-
vation of NF-κB and other pro-inflammatory signals in
CD44+ ovarian CSCs appeared to correlate with chemore-
sistance to paclitaxel and carboplatin [89]. Inhibition of
NF-κB by Eriocalyxin B induced cell death in chemoresis-
tant CD44+ ovarian CSCs [90]. In breast CSCs, treatment
with disulfiram and copper can inhibit consitutively active
NF-κB while sensitizing these cells to paclitaxel [91].
There are likely a number of other signaling pathways that
also can contribute to chemoresistance in CSCs that is
likely dependent on the cell origin as well as other genetic
alteration that drive the formation of these CSCs beyond
those summarized in this review (Table 1).
Altered DNA damage response in CSCs
A major mechanism that contributes to cancer progres-
sion and chemoresistance is an enhanced DNA damage
response. Under hypoxic conditions, tumor cells can in-
duce a potent DNA damage response primarily through
hypoxia-inducible factor transcription factors [92]. Follow-
ing this initial detection of hypoxia and response to DNA
damage, two major signaling pathways are activated, ataxia
telangiectasia mutated (ATM) and ATM and Rad-3-related
(ATR) [93]. ATM and ATR can subsequently regulate cell
cycle by phosphorylating downstream kinases checkpoint
kinase 2 (CHK2) and checkpoint kinase 1 (CHK1), respect-
ively. Following activation, ATM/CHK2 and ATR/CHK1
repressively phosphorylate cell division cycle 25 homo-
log B (CDC25B) and cell division cycle 25 homolog A
(CDC25A). This in turn impairs CDC25 family member
activation of cyclin dependent kinases (CDKs) and G1/S
and G2/M transitions [94].
The very mechanisms that regulate cell cycle and pro-
mote DNA damage repair can also protect CSCs from
DNA damaging radiation therapy and chemotherapeu-
tics, particularly cytotoxic drugs that target tumor cell
DNA. Analyzing CD133+ glioma stem cells, Bao et al.
demonstrated that these cells were more resistant to ion-
izing radiation than CD133- cells and could be enriched
following radiation therapy [95]. Following radiation,
CD133+ glioma stem cells exhibited much higher acti-
vated phosphorylation of DNA damage response factors
ATM, CHK1 and CHK2 than CD133- glioma cells. Fur-
thermore, inhibition of CHK1/CHK2 with debromohy-
menialdisine reversed radioresistance in CD133+ glioma
stem cells. Gallmeier et al. saw similar results in CD133+
colon CSCs where CD133+ colon CSCs appeared to be
more resistant to DNA interstrands crosslinking (ICL)
Table 1 Summary of chemoresistance-related signaling pathways in this review
Transcription factor/
signaling pathway
Tumor type Drug resistance References
MYC Hepatocellular Carcinoma, Leukemia, Paclitaxel, Doxorubicin, 18, 56, 64
AKT/PKB Hepatocellular Carcinomaxx Doxorubicin, 5-Fluorouracil 68




74, 75, 76, 77
Notch Colon Cancer, Ovarian Cancer, Glioma Oxaliplatin, Cisplatin, Temozolomide 79, 80, 81, 82




82, 84, 85, 86, 87
NF-κB Ovarian Cancer, Breast Cancer Paclitaxel, Carboplatin, 88, 89, 90
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[96]. Treatment of colon cancer cells with ICL agents
resulted in a more pronounced increase in phosphorylation
of CHK1 in CD133+ colon CSCs compared with CD133-
colon cancer cells. A role for CHK1 in chemoresistance in
these colon CSCs was demonstrated by inhibition of CHK1
by SB218078 resulting in increased sensitivity of CD133+
colon CSCs to cisplatin. Similar sensitization to gemcita-
bine with CHK1 inhibitors was also seen in chemoresistant
CD24+CD44+ESA+ pancreatic cancer stem cells as well
[97]. This work provided more evidence that inhibition ofFigure 1 Molecular Mechanisms of CSC Chemoresistance (A). ABC tra
cancer cells. The specific ABC transporter pump expressed in the CSCs de
enzyme, whereas other isoforms can localize to the mitochondria as well a
cyclophosphamide is reduced in ALDH expressing CSCs, as these drugs are
pro-apoptotic proteins BAX and BAK, preventing the release of the apopto
BCL-2 and other pro-survival BCL-2 family members utilize this mechanism
damage, ATM and ATR recognize breaks in DNA and activate CHK2 and CH
DNA repair. Activation of these DNA repair proteins in CSCs can impair theCHK1 and the DNA damage response may be an effective
method for targeting and treating chemoresistant CSCs.
Conclusion
CSCs can escape the toxic effects of chemotherapy
through a variety of mechanism, including some not dis-
cussed in this review. Some of these mechanisms can be
exploited as methods to diagnosis and identify CSCs while
others have been previously identified as key mechanisms
in overall tumor cell survival (Figure 1). Studies with spe-
cific oncogene models of cancer and studies of specificnsporters can efflux a wide variety of chemotherapeutics out of
termines the specificity of chemoresistance. (B). ALDH1 is a cytosolic
s the cytosol. The efficacy of chemotherapeutic drugs such as
substrates for these enzymes. (C). Pro-survival protein BCL-2 binds to
genic factor cytochrome c from the mitochondria. Aberrant activity of
to prevent chemotherapy-mediated apoptosis. (D). Following DNA
K1, respectively. CHK2 and CHK1 can impair cell cycle and promote
efficacy of ICL agents.
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and oncogenic factors can determine the mechanism by
which CSCs mediate chemoresistance. Many of the stu-
dies highlighted in this review provide evidence that CSCs
can be targeted and treated to improve overall therapy. As
cancer treatment moves towards a more personalized
medical approach, proper diagnosis paired with targeted
and informed approaches to treating specific types of
CSCs may prove to be a useful method for overcoming
drug treatment failures that ultimately lead to recurrence
and death.
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